tirzepatide cv outcomes ๐ In a large real-world study, was associated with a lower incidence of major cardiovascular vs semaglutide: ๐ Composite outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) โค๏ธ New-onset heart Tirzepatide cardiovascular event risk assessment:
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Sep 23 - Sep 28








:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)








,type=downsize)





